breast cancer
PMI
The National Institute for Health and Clinical Excellence, (NICE), has opened a consultation on draft guidance which does not recommend bevacizumab (Avastin, Roche), for metastatic breast cancer, when used in combination with the chemotherapy drug, capecitabine....
18 April 2012
•
PMI
Two more cancer drugs have been provisionally banned for NHS after it was decided they were too expensive for the potential results.
14 February 2012
•
2 min read
PMI
The PIP breast implant furore could prompt the creation of an insurance scheme for cosmetic surgery patients to prevent similar remedial problems in the future.
20 January 2012
•
1 min read
PMI
The National Institute for Health and Clinical Excellence (Nice) has banned another breast cancer drug from routine NHS use.
10 November 2011
•
2 min read
Critical Illness
Aviva has added the first partial payments to its critical illness (CI) policy and halved the length of time for a Multiple Sclerosis (MS) claim.
17 October 2011
•
1 min read
PMI
The National Institute for Health and Clinical Excellence (NICE) has rejected another cancer drug for the NHS due to its cost.
22 August 2011
•
2 min read
PMI
The NHS exceeded all seven of its targets for cancer diagnosis and treatment during the last year, new data has revealed.
19 August 2011
•
1 min read
Critical Illness
Bright Grey and Scottish Provident have sought to clarify breast cancer cover from critical illness (CI) providers following recent changes made to their definitions.
15 June 2011
•
2 min read
PMI
The National Institute for Health and Clinical Excellence (Nice) has rejected the use of Avastin for metastatic breast cancer on the NHS.
23 February 2011
•
1 min read
Underwriting
Julie Hopkins considers the case for adding partial benefit payment for DCIS treated with mastectomy and asks whether coverage could be extended to all DCIS diagnoses resulting in surgery
09 August 2010
•
7 min read
